Table 1.
Baseline characteristics of 1660 patients who were disease-free at 3 years after randomisation.
| Characteristica | 6-year anastrozole (N = 827) | 3-year anastrozole (N = 833) |
|---|---|---|
| Median age – years (IQR) | 57 (51–64) | 57 (51–64) |
| Age at randomisation – no. (%) | ||
| <60 years | 483 (58) | 488 (59) |
| ≥60 years | 344 (42) | 345 (41) |
| Pathological tumour status – no. (%) | ||
| T1 | 376 (45) | 383 (46) |
| T2 | 392 (47) | 382 (46) |
| T3/4 | 58 (7) | 67 (8) |
| Unknown | 1 (<1) | 1 (<1) |
| Pathological nodal status – no. (%) | ||
| Negative | 266 (32) | 282 (34) |
| Positive | 561 (68) | 551 (66) |
| Tumour grade – no. (%) | ||
| G1 | 139 (17) | 158 (19) |
| G2 | 430 (52) | 415 (50) |
| G3 | 229 (28) | 238 (29) |
| Unknown | 29 (4) | 22 (3) |
| Hormone receptor status – no. (%) | ||
| ER+/PR+ | 627 (76) | 633 (76) |
| ER+/PR- | 188 (23) | 181 (22) |
| ER-/PR+ | 12 (2) | 19 (2) |
| HER2 status – no. (%) | ||
| Positive | 18 (2) | 22 (3) |
| Negative | 745 (90) | 748 (90) |
| Unknown | 64 (8) | 63 (8) |
| Histology – no. (%) | ||
| Ductal | 606 (73) | 636 (76) |
| Breast-conserving surgery – no. (%) | ||
| Yes | 433 (52) | 408 (49) |
| Prior (neo) adjuvant chemotherapy – no. (%) | ||
| Yes | 565 (68) | 570 (68) |
| Previous use of tamoxifen – no. (%) | ||
| ≤2.5 years | 606 (73) | 598 (72) |
| >2.5 years | 221 (27) | 235 (28) |
Percentages may exceed 100% because of rounding.
ER = oestrogen receptor, HER2 = human epidermal growth factor receptor 2, IQR = interquartile range, PR = progesterone receptor.
a
There were no statistically significant differences in baseline characteristics between the groups.